Failure to evaluate REMS risk early can create avoidable launch risks, including compressed implementation timelines, increased costs, and delayed market entry.
Louisiana’s recent enactment of Senate Bill 401 is another step forward in the evolution of state-level oversight of prescription drug pricing. Effective January 1, 2027, this legislation establishes a Prescription Drug Affordability Board (PDAB) within the Louisiana Department of Insurance and introduces an enhanced and new framework for manufacturer reporting on prescription drug pricing. While the legislation outlines several reporting requirements, many of the operational details surrounding implementation have yet to be defined.
While faster review timelines may help advance innovation in areas of significant unmet need, they also bring a more immediate strategic question for manufacturers: how do you accelerate access without creating downstream risk for patients, providers, or the product itself?
Once contracts are signed and workflows are built, changing course becomes complex, disruptive, and highly visible.
The good news? With the right strategic alignment and disciplined implementation, this decision can become a powerful accelerant for launch success.
